In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal Statistics, Q4 2013

A look at financing, M&A, and alliance activity, October–December 2013

Executive Summary

Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.

Advertisement

Related Content

Device/Diagnostics Quarterly Deal Statistics, Q4 2014
Covidien Buys Given To Build GI Business Base In Biggest Israeli Medtech Deal
Spine Tingling After LDR Holdings’ IPO
CareFusion Acquires GE Healthcare’s Clinical Consumables Division
Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
Option-To-Acquire In Medical Device Deals Rarely Gets Exercised
Covidien Still Hungry For GI After Barrx Buy
Boston Scientific Spins Out TriVascular AAA Biz To Investors For $30 Mil.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel